<DOC>
	<DOCNO>NCT02584517</DOCNO>
	<brief_summary>Giant Cell Arteritis ( GCA ) common vasculitis significant morbidity term blindness , stroke , tissue necrosis . It require protracted treatment high-dose steroid , despite risk flare treatment . Little known initial trigger inflammatory process , good marker response relapse . We study patient refer suspected GCA identify important component immune response GCA , follow time collect evidence best monitor condition .</brief_summary>
	<brief_title>Aetiology TemporaL Arteritis Study</brief_title>
	<detailed_description>Objectives Study Plan : Study Purpose : The purpose study investigate underlying immunological process GCA study pattern expression immune response time give u information best monitor GCA . End Point : The end point final visit final patient . Milestones : The project 3 phase . In phase 1 ( 0-2 year ) patient recruit fulfil specify primary secondary objective . In phase 2 ( 0-4 year ) , patient follow total 2 year , discharge clinic . In phase 3 ( 1-5 year ) , study define tissue data collect amended ethic .</detailed_description>
	<mesh_term>Arteritis</mesh_term>
	<mesh_term>Giant Cell Arteritis</mesh_term>
	<criteria>1 . 18 year age 2 . A clinical suspicion new diagnosis GCA e.g . patient new onset headache , scalp tenderness , without elevate CRP ESR , jaw tongue claudication without visual loss 3 . Participants must willing give informed write consent willing give permission nominate friend relative provide write informed assent unable physical disability e.g . sudden onset blindness/vision loss cause GCA ( make clear ethic approval application ) 1 . Previous diagnosis GCA 2 . Long term ( &gt; 1 month ) high dose ( &gt; 20mg per day time ) steroid condition PMR , within three month prior study entry 3 . Inability give inform consent ( either write consent verbal assent relative carer )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Vasculitis</keyword>
	<keyword>Autoimmune disease</keyword>
	<keyword>Connective tissue disease</keyword>
	<keyword>Polymyalgia rheumatica</keyword>
	<keyword>Musculoskeletal Diseases</keyword>
	<keyword>Immune disorder</keyword>
	<keyword>Rheumatic disease</keyword>
</DOC>